RHYTHM Biosciences Ltd Total Assets
RHYTHM Biosciences Ltd total assets. Based on the latest financial reports, RHYTHM Biosciences Ltd (RHY) holds total assets worth AU$3.10 Million AUD (≈ $2.19 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see RHY market cap overview for the company's overall valuation and market capitalisation.
Total Assets of RHYTHM Biosciences Ltd (2017–2025)
Total assets of RHYTHM Biosciences Ltd from 2017 to 2025. This chart illustrates how RHYTHM Biosciences Ltd's total assets have evolved over time, based on quarterly financial data. See RHYTHM Biosciences Ltd share price for real-time trading data and today's change.
RHYTHM Biosciences Ltd - Asset Composition Analysis
RHYTHM Biosciences Ltd Total Assets Breakdown (June 2025)
RHYTHM Biosciences Ltd total assets breakdown as of June 2025. RHYTHM Biosciences Ltd's total assets of AU$3.10 Million consist of 64.0% current assets and 36.0% non-current assets.
| Asset Category | Amount (AUD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$0.00 | 49.3% |
| Accounts Receivable | AU$61.91K | 2.2% |
| Inventory | AU$74.36K | 2.6% |
| Property, Plant & Equipment | AU$171.03K | 6.0% |
| Intangible Assets | AU$318.13K | 11.2% |
| Goodwill | AU$531.02K | 18.8% |
Asset Composition Trend (2017–2025)
This chart illustrates how RHYTHM Biosciences Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore RHYTHM Biosciences Ltd short-term liquidity ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: RHYTHM Biosciences Ltd's current assets represent 64.0% of total assets in 2025, a decrease from 96.8% in 2017.
- Cash Position: Cash and equivalents constituted 49.3% of total assets in 2025, down from 96.5% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 29.0% of total assets, an increase from 3.0% in 2017.
- Asset Diversification: The largest asset category is goodwill at 18.8% of total assets.
RHYTHM Biosciences Ltd Competitors by Total Assets
Key competitors of RHYTHM Biosciences Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Voxel S.A.
WAR:VOX
|
Poland | zł746.13 Million |
|
Leveljump Healthcare Corp
V:JUMP
|
Canada | CA$18.29 Million |
|
Prodia Widyahusada Tbk PT
JK:PRDA
|
Indonesia | Rp2.57 Trillion |
|
Sonic Healthcare Ltd
AU:SHL
|
Australia | AU$16.78 Billion |
|
Integral Diagnostics Ltd
AU:IDX
|
Australia | AU$1.43 Billion |
|
Australian Clinical Labs Ltd
AU:ACL
|
Australia | AU$562.50 Million |
|
Healius Ltd
AU:HLS
|
Australia | AU$1.77 Billion |
|
Monash Ivf Group Ltd
AU:MVF
|
Australia | AU$512.35 Million |
RHYTHM Biosciences Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.31 | 4.87 | 9.95 |
| Quick Ratio | 2.23 | 4.79 | 9.95 |
| Cash Ratio | 0.00 | 0.00 | 9.62 |
| Working Capital | AU$1.23 Million | AU$3.84 Million | AU$5.60 Million |
RHYTHM Biosciences Ltd - Advanced Valuation Insights
This section examines the relationship between RHYTHM Biosciences Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 28.31 |
| Latest Market Cap to Assets Ratio | 5.16 |
| Asset Growth Rate (YoY) | 86.5% |
| Total Assets | AU$2.83 Million |
| Market Capitalization | $14.62 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values RHYTHM Biosciences Ltd's assets at a significant premium (5.16x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: RHYTHM Biosciences Ltd's assets grew by 86.5% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for RHYTHM Biosciences Ltd (2017–2025)
The table below shows the annual total assets of RHYTHM Biosciences Ltd from 2017 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-06-30 | AU$2.83 Million ≈ $2.00 Million |
+86.46% |
| 2024-06-30 | AU$1.52 Million ≈ $1.07 Million |
-80.26% |
| 2023-06-30 | AU$7.70 Million ≈ $5.45 Million |
-8.80% |
| 2022-06-30 | AU$8.44 Million ≈ $5.97 Million |
+174.87% |
| 2021-06-30 | AU$3.07 Million ≈ $2.17 Million |
+16.02% |
| 2020-06-30 | AU$2.65 Million ≈ $1.87 Million |
-57.53% |
| 2019-06-30 | AU$6.23 Million ≈ $4.41 Million |
-26.27% |
| 2018-06-30 | AU$8.45 Million ≈ $5.98 Million |
+445.29% |
| 2017-06-30 | AU$1.55 Million ≈ $1.10 Million |
-- |
About RHYTHM Biosciences Ltd
Rhythm Biosciences Limited, a medical diagnostics company, provides blood tests for the detection of cancers in Australia and the United States. It offers ColoSTAT, a blood test for the early detection of colorectal cancer; and geneType, a personalized predictive test for predicting risk of chronic disease development. The company was incorporated in 2017 and is headquartered in Parkville, Austra… Read more